Trials / Completed
CompletedNCT00614250
Evaluation of the Effect of AVE0657 on Obstructive Sleep Apnea
A Double-blind, Randomized, Placebo-controlled, Study of the Safety and Activity of Four Escalating Single Doses of AVE0657 in Patients Suffering From Obstructive Sleep Apnea Hypopnea Syndrome
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the activity of 4 escalating doses of AVE0657 in comparison to placebo in patients with Obstructive Sleep Apnea Hypopnea Syndrome.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AVE0657 | capsules once a day at bedtime |
| DRUG | placebo | capsules once a day at bedtime |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-01-01
- Completion
- 2009-01-01
- First posted
- 2008-02-13
- Last updated
- 2009-07-20
Locations
3 sites across 3 countries: France, Germany, Spain
Source: ClinicalTrials.gov record NCT00614250. Inclusion in this directory is not an endorsement.